Biotechnology company BeiGene and Ontada, a McKesson Corporation business providing technology and real-world evidence (RWE), research, and education to oncology practices, announced a collaboration on August 15 to “improve US community oncology care through the development of real-world evidence data, tools, and insights to help increase access to affordable cutting-edge therapies.”
According to a joint statement from the companies, Ontada will lead the partnership, with a focus on the use of RWE to underscore the value of oncolytics and to improve patient access to oncology therapies. As part of the partnership, the companies will:
Christiane Langer, MD, senior vice president of Global Medical Affairs (Ex-China) for BeiGene, said the company seeks to bring 10 molecules per year to the clinic starting in 2023. “As this research advances, we’re delighted to form this strategic partnership with McKesson, which shares the same vision as BeiGene for improving the care of cancer patients,” Langer said in the statement.
“This collaboration will leverage Ontada’s technology platform and deep understanding of the experiences of patients treated in community oncology clinics to help accelerate both the development of the BeiGene portfolio and expand access to treatment options.”
“Ontada is uniquely positioned to support complex research that uncovers deeper patient insights and perspectives that advance cancer care,” Susan Shiff, PhD, MBA, president of Ontada, said in the statement. “We are excited to announce this unique partnership with BeiGene and look forward to developing a stronger understanding of how to better treat oncology patients through the use of real-world data and evidence.”
“BeiGene is excited to work with Ontada to advance our shared vision of improving patient access, affordability, and value for community oncology stakeholders and key partners working at the intersection of clinical practice and real-world evidence,” said Josh Neiman, MBA, BeiGene’s chief commercial officer for North America and Europe. “Working together, BeiGene and Ontada will generate novel oncology insights through real-world data, tools, and technologies that will facilitate the acceleration of precise decision-making in support of community oncology practices whose ultimate mission is to improve patient outcomes.”
Reference
BeiGene announces strategic alliance with Ontada to improve US community oncology care. News release. BeiGene. August 15, 2022. Accessed September 21, 2022. https://bit.ly/3f5Qxr4
Bringing Connectivity to the Specialty Pharmacy Workflow
May 2nd 2024In a session during the final full day of conference activity at AXS24, experts from CVS Health and Surescripts emphasized the need to simplify the prescribing workflow for specialty medication through proactive messaging, automation, and interoperability.
Read More
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More